Clinical Trial

A Study of FDA018-ADC in Patients With Advanced Solid Tumors

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a Phase 1, open-label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics and efficacy of FDA018-ADC in patients with advanced/metastatic solid tumors.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2021-12-14; most recent amendment 2026-01-21.
Status change: Recruiting → Active, Not Recruiting 2025-03-06
Trial Details
NCT Number NCT05174637
Lead Sponsor Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Conditions Advanced/ Metastatic Solid Tumors
Enrollment 78 participants
Start Date 2021-10-22
Primary Completion 2029-12 (estimated)
Study Completion 2029-12 (estimated)
Updated on ClinicalTrials.gov 2026-01-23